01
MC3R/MC4R
Bremelanotide activates central melanocortin receptors involved in sexual response.
Melanocortin-receptor agonist
PT-141 / Bremelanotide
MC3R/MC4R
PT-141 is the research name for bremelanotide, a central melanocortin-receptor agonist. The approved medicine has a specific formulation, indication, contraindications and use limits; a research vial is not automatically equivalent.
1Overview
—Reference frequency
DataRandomised phase 3 trials
Research status
Bremelanotide is US-approved for a specific HSDD indication
PT-141 BREMELANOTIDE10 MG
01 · Overview
What is PT-141 / Bremelanotide?
PT-141 is the research name for bremelanotide, a central melanocortin-receptor agonist. The approved medicine has a specific formulation, indication, contraindications and use limits; a research vial is not automatically equivalent.
Research route, formulation and population determine what a result actually means.
02 · Research
What do the studies show?
Randomised phase 3 trials. Educational information. Not diagnosis, treatment or use advice.
2 trials
Phase 3RECONNECT programme
Two identical phase 3 trials found a statistical benefit for desire and related distress in premenopausal women with HSDD.
1.75 mg
Approved active substanceLabel dose is indication-specific
Nausea and transient blood-pressure increases are important warnings; the product is not intended for general sexual performance enhancement.
03 · DATA
Peptide and product specifications
Checked identity data for this research compound or blend.
PT-141 / BremelanotidePeptide and product specifications
Molecular formula
C₅₀H₆₈N₁₄O₁₀
Molecular weight
1025.16 g/mol
CAS number
189691-06-3
Amino-acid sequence / components
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Amino-acid count
7
Purity
Batch-specific — confirm identity and purity with the Velora COA
Reference form
White lyophilised powder
Reference diluent
Formulation- and batch-specific; there is no universal diluent for every research compound
Unreconstituted-material storage
Follow the accompanying COA, product label and validated stability data
These are compound references, not a batch certificate. Purity and identity of a specific Velora batch must be confirmed by its accompanying COA and laboratory report.
04 · Calculator
Reconstitution and U-100 conversion
This module only converts concentration and volume. Inputs are not recommendations or individual dosing advice.
Calculator
As needed in the approved medicine label
1
2
3
4
Draw to
0 units
0.00 mL
PT-141 BREMELANOTIDE
10 MG
Concentration—
Per unit—
Complete amounts—
Calculated duration—
LAB · RECONSTITUTION
How to reconstitute PT-141 / Bremelanotide for laboratory research
A visual workflow for controlled laboratory reconstitution. Always follow the product label, COA and a validated protocol.
Clean
Disinfect the rubber closures of both vials and allow them to dry.
Measure diluent
Withdraw only the diluent validated for the specific compound.
Add slowly
Let the liquid run slowly down the inside wall of the vial.
Swirl gently
Do not shake; rotate gently until the material has dissolved.
Store per protocol
Follow the product label, COA and validated stability data.
Important checks before and after reconstitution
Check the product
First confirm that the product is a lyophilised vial. Prefilled pens and ready-to-use solutions do not require reconstitution. Check the label, COA and specified diluent.
Use clean, sterile technique
Wash your hands, clean the work surface and use new sterile equipment for every procedure. Clean both rubber closures with separate alcohol swabs and let them dry completely.
Concentration, not total amount
The volume of liquid added changes the concentration in mg per mL, but not the total amount of research compound in the vial. Use the calculator to check this in advance.
Inspect and label
Check for unexpected discoloration, cloudiness or visible particles. Record the compound, concentration and reconstitution date. Storage time and temperature are product-specific; a fixed 28-day rule does not apply to every compound.
General reconstitution volumes listed by the source
General examples, not a product-specific protocol. The chosen volume determines concentration; always check the label, COA and calculator.
| Vial strength | Commonly listed volume |
|---|---|
| 2 mg | 1–2 mL |
| 5 mg | 2–3 mL |
| 6 mg | 2–3 mL |
| 10 mg | 2–4 mL |
| 15 mg | 3–5 mL |
| 20 mg | 4–8 mL |
Practical background source: Free Medical Journals — Complete Step-by-Step Guide to Peptide Reconstitution, accessed July 2026. This is a secondary educational source; the product label, COA and validated stability data remain authoritative.
05 · Safety and limitations
Safety and limitations
Research route, formulation and population determine what a result actually means.
What is known
- Visible research claims use primary or official sources.
- The calculator is arithmetic and does not turn a study amount into medical advice.
- A registered medicine and a research vial are not automatically equivalent.
What remains uncertain
- Many products lack long-term safety data and independent replication.
- Animal and cell findings do not predict a safe human dose.
- Stability depends on formulation, pH, sterility, light, temperature and packaging.
Status: Bremelanotide is US-approved for a specific HSDD indication. Educational information. Not diagnosis, treatment or use advice.
06 · FAQ
Frequently asked questions
PT-141 is the research name for bremelanotide, a central melanocortin-receptor agonist. The approved medicine has a specific formulation, indication, contraindications and use limits; a research vial is not automatically equivalent.
Two identical phase 3 trials found a statistical benefit for desire and related distress in premenopausal women with HSDD. Nausea and transient blood-pressure increases are important warnings; the product is not intended for general sexual performance enhancement.
No. It performs arithmetic conversions only. Medical decisions belong with a licensed healthcare professional.
The curve follows the agreed storage model and is not a laboratory result.
2–8 °C. Protect from light and repeated freeze-thaw cycles.